From the Department of Pharmacology, Faculty of Medicine, Université de Montréal, Montreal, Quebec H3C 3J7 and.
J Biol Chem. 2014 Feb 28;289(9):5687-703. doi: 10.1074/jbc.M113.516047. Epub 2014 Jan 9.
Signals downstream of growth factor receptors play an important role in mammary carcinogenesis. Recently, we demonstrated that the small GTPases ARF1 and ARF6 were shown to be activated downstream of the epidermal growth factor receptor (EGFR) and act as a key regulator of growth, migration, and invasion of breast cancer cells. However, the mechanism via which the EGFR recruits and activates ARF1 and ARF6 to transmit signals has yet to be fully elucidated. Here, we identify adaptor proteins Grb2 and p66Shc as important regulators mediating ARF activation. We demonstrate that ARF1 can be found in complex with Grb2 and p66Shc upon EGF stimulation of the basal-like breast cancer MDA-MB-231 cell line. However, we report that these two adaptors regulate ARF1 activation differently, with Grb2 promoting ARF1 activation and p66Shc blocking this response. Furthermore, we show that Grb2 is essential for the recruitment of ARF1 to the EGFR, whereas p66Shc hindered ARF1 receptor recruitment. We demonstrate that the negative regulatory role of p66Shc stemmed from its ability to block the recruitment of Grb2/ARF1 to the EGFR. Conversely, p66Shc potentiates ARF6 activation as well as the recruitment of this ARF isoform to the EGFR. Interestingly, we demonstrate that Grb2 is also required for the activation and receptor recruitment of ARF6. Additionally, we show an important role for p66Shc in modulating ARF activation, cell growth, and migration in HER2-positive breast cancer cells. Together, our results highlight a central role for adaptor proteins p66Shc and Grb2 in the regulation of ARF1 and ARF6 activation in invasive breast cancer cells.
生长因子受体下游信号在乳腺肿瘤发生中起着重要作用。最近,我们证明,小 GTPases ARF1 和 ARF6 在表皮生长因子受体 (EGFR) 下游被激活,并作为乳腺癌细胞生长、迁移和侵袭的关键调节因子。然而,EGFR 招募和激活 ARF1 和 ARF6 以传递信号的机制尚未完全阐明。在这里,我们确定衔接蛋白 Grb2 和 p66Shc 是重要的调节因子,介导 ARF 的激活。我们证明,在基础型乳腺癌 MDA-MB-231 细胞系中 EGF 刺激后,ARF1 可以与 Grb2 和 p66Shc 形成复合物。然而,我们报告说这两种衔接蛋白以不同的方式调节 ARF1 的激活,Grb2 促进 ARF1 的激活,而 p66Shc 则阻断这种反应。此外,我们表明 Grb2 对于 ARF1 向 EGFR 的募集是必不可少的,而 p66Shc 则阻碍了 ARF1 受体的募集。我们证明,p66Shc 的负调节作用源于其阻止 Grb2/ARF1 向 EGFR 募集的能力。相反,p66Shc 增强了 ARF6 的激活以及这种 ARF 同工型向 EGFR 的募集。有趣的是,我们证明 Grb2 对于 ARF6 的激活和受体募集也是必需的。此外,我们表明 p66Shc 在调节 HER2 阳性乳腺癌细胞中的 ARF 激活、细胞生长和迁移方面起着重要作用。总之,我们的结果突出了衔接蛋白 p66Shc 和 Grb2 在调节侵袭性乳腺癌细胞中 ARF1 和 ARF6 激活中的核心作用。